2023 Volume 82 Issue 2 Pages 77-85
Recent advances in novel cancer therapies have resulted in a growing number of survivors of cancer. Nevertheless, it is increasingly clear from the results of a childhood cancer survivor study that the therapies that cured theirprimary malignancies place them at increased, life-long risk for cardiovascular complications. In this manuscript,we briefly reviewed the essence of existing clinical guidelines and related studies on cardiomyopathy surveillancefor survivors of childhood cancer, including the topics of 1) the timeline of evolution on Cardio-Oncology, 2) abackground of needs on Cardio-Oncology, 3) a concept of cancer therapy-related cardiac dysfunction (CTRCD),4) diagnostic tools for CTRCD, 5) recent key studies on Cardio-Oncology, and 6) a new clinical trial of cardiomyopathy surveillance for survivors of childhood cancer, underscoring the clinical importance of this new interdisciplinary field.
